Changes in Hong Kong stocks | Jinhai Medical Technology (02225) rose more than 14%, and Korean investors bucked the trend and increased the company's position to further cultivate the field of minimally invasive surgery in China

The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose by more than 14%. As of press release, it had risen 14.64% to HK$4.15, with a turnover of HK$147 million.

According to the news, data from the securities information portal (SeiBro) under the Korea Securities Depository and Settlement Institute shows that in the past week, at a time when global technology stocks have been drastically adjusted, Korean investors have used real money to increase their positions in Chinese assets. In the Hong Kong stock market, the net purchase amount for the target products, including Jinhai Medical Technology, was also over one million US dollars.

According to reports, Jinhai Medical focuses on overall solutions for minimally invasive medical devices such as high-end medical endoscopes. With continuous deep cultivation in the field of endoscopic technology research and development in recent years, Jinhai has achieved many important breakthroughs. Mr. He Xiao, the company's chief marketing officer, previously stated, “We will continue to invest in fields such as spine and surgical products for the next three years, especially in the field of minimally invasive spinal AI, and we are also seeking a new breakthrough.”